PetCaseFinder

Peer-reviewed veterinary case report

Does famotidine IV drip raise stomach acid in healthy dogs

By Hedges, Katherine et al.·Published in Journal of veterinary internal medicine·2019·University of Tennessee College of Veterinary Medicine·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Evaluation of the effect of a famotidine continuous rate infusion on intragastric pH in healthy dogs.

Species:
dog

Plain-English summary

Nine healthy Beagle dogs were given famotidine, a medication that helps reduce stomach acid, either through a continuous rate infusion (CRI) or as a standard injection twice a day. The study found that the CRI method significantly raised the stomach's acidity level, which is important for healing gastrointestinal ulcers. The dogs receiving the CRI maintained a higher pH level in their stomachs compared to those on the standard treatment. This suggests that using famotidine as a CRI could be a more effective option for treating stomach issues in dogs.

People also search for: dog stomach acid treatment · famotidine for dogs · gastrointestinal ulcers in dogs

Abstract

BACKGROUND: Famotidine is sometimes administered as a continuous rate infusion (CRI) to treat gastrointestinal ulceration in critically ill dogs. However, clinical studies have not evaluated the efficacy of a famotidine CRI in dogs. HYPOTHESIS/OBJECTIVES: To evaluate the efficacy of famotidine at raising intragastric pH when it is administered as a CRI in dogs. We hypothesized that CRI treatment with famotidine would meet clinical goals for raising intragastric pH &#x2265;3 and 4. ANIMALS: Nine healthy Beagle dogs. METHODS: Randomized 2-way crossover. All dogs received 1.0 mg/kg IV q12h famotidine or CRI famotidine at 1.0 mg/kg IV loading dose and 8.0 mg/kg/d for 3 consecutive days. Beginning on day 0 of treatment, intragastric pH monitoring was used to continuously record intragastric pH. Mean percentage times (MPTs) for which intragastric pH was &#x2265;3 and &#x2265;4 were compared between groups using analysis of variance. RESULTS: There was a statistically significant difference (P&#x2009;<&#x2009;.05) in MPT &#x2265;3 and &#x2265;4 between the CRI and IV q12h groups on all treatment days. On days 1, 2, and 3, the MPTs&#x2009;&#xb1;&#x2009;SD for which pH was &#x2265;3 were 92.1&#x2009;&#xb1;&#x2009;8.5, 96.3&#x2009;&#xb1;&#x2009;6.2, and 90.0&#x2009;&#xb1;&#x2009;15.7 for the CRI treatment group and 49.3&#x2009;&#xb1;&#x2009;27.3, 42.2&#x2009;&#xb1;&#x2009;19.6, and 45.8&#x2009;&#xb1;&#x2009;10.1, respectively, for the twice-daily group. CONCLUSIONS AND CLINICAL IMPORTANCE: These results suggest that a famotidine CRI, but not standard doses of famotidine, achieves the clinical goals established in people to promote healing of gastric tissue injury and offers an alternative to intravenous treatment with proton pump inhibitors in dogs.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31294879/